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Patients who experience multiple hospitalizations over short periods of time may be at 
greater risk of hospital-acquired infections (HAIs). While it is known that prior hospitalizations 
are associated with HAIs, there is a gap in knowledge regarding which factors of prior 
hospitalizations have an impact on the risk of HAIs in subsequent hospitalizations. HAIs caused 
by gram-negative bacteria (GNB) are of particular concern due to their propensity to develop drug 
resistance and the limited antibiotics available to treat them. The aims of this dissertation are to: 
1) examine clinical and patient risk factors associated with acquiring at least one gram-negative 
hospital-acquired infection in adult patients with multiple hospitalizations; 2) systematically 
review the literature assessing the association between repeat gram-negative bacterial infections 
and changes in antibiotic susceptibility patterns; and 3) assess the association between repeat 
infections with three common gram-negative pathogens and risk of subsequent drug resistant 
infections with the same species among patients with multiple hospitalizations. 
A retrospective cohort study was conducted to identify risk factors from prior 
hospitalizations associated with incident HAIs caused by three common GNB.   Of the 129,372 
patients with multiple hospitalizations, 1,672 (1.3%) acquired K. pneumoniae, 1,127 (0.9%) 
acquired P. aeruginosa, and 262 (0.2%) acquired A. baumannii infections. In survival analyses, 
older age, mechanical ventilation, history of chronic diseases, and increasing days of use of 
  
antibiotics decreased the time to infection for all 3 pathogens. This study highlights potential 
modifiable risk factors for infection control. 
Patients with multiple hospitalizations are also inherently at greater risk for repeat HAIs 
which may result in decreased antibiotic susceptibility, making them more difficult to treat. A 
systematic review was conducted to evaluate if there is an association between repeat GNB HAIs 
and drug resistance. From 2000 to 2015, only seven studies explicitly examined repeat GNB HAIs 
and change in antibiotic susceptibility, five of which reported decreased susceptibility in later 
infections. 
The association between repeat GNB HAIs and risk of drug resistance among patients with 
multiple hospitalizations was then investigated with available electronic medical record data. The 
risk of a drug-resistant K. pneumoniae HAI increased by 1.14 times (95%CI: 1.04-1.24) with each 
prior K. pneumoniae HAI, after adjusting for potential confounders and antibiotic use. Similarly, 
patients with repeat P. aeruginosa infections had a 1.23 times increased risk of a subsequent drug-
resistant infection (95%CI: 1.12-1.36) with each prior P. aeruginosa HAI as compared to patients 
with only one infection. Repeat A. baumannii infections were not analyzed due to limited sample 
size. 
The studies in this dissertation demonstrate that patients with multiple hospitalizations are 
a high-risk population for GNB HAIs. Prevention of GNB HAIs in this group is critical in order 
to reduce complications to medical care and limit transmission of infections to others in healthcare 
facilities and the community. Patient medical history can be used for infection risk assessment and 
to guide future medical care to reduce risk of infection in patients with multiple hospitalizations.
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Hospital-acquired infections (HAIs) are often preventable and yet continue to account for 
a significant number of complications in hospitalized patients. In 2014, a landmark study reported 
that 1 in every 25 patients hospitalized in the United States acquired a HAI [1]. In addition to the 
$5.7 to $6.5 billion in attributable annual healthcare costs for the US, HAIs are associated with 
substantial complications and deaths in hospitalized patients, particularly those in intensive care 
units (ICUs) [2, 3]. In older adults, such infections cause a two-fold increase in 90-day mortality 
rate and an average of 10 additional days in the hospital [4]. 
 
1.1 Gram-negative bacteria 
 
Gram-negative bacteria (GNB) are implicated as the causative organisms in 20% of HAIs 
in hospital settings and 60% of HAIs in intensive care units [1, 5]. In hospital settings, three of the 
primary GNB of interest are Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter 
baumannii [6], all three of which cause opportunistic infections and have unique features that make 
them particularly pathogenic in hospital settings. GNB differ from gram-positive bacteria in that 
their cell structure has only a thin peptidoglycan cell wall and an outer membrane, with the latter 
acting as an extra protective layer against antibiotics. This additional protection means that a 
limited number of antibiotic classes are effective in destroying GNB [6]. Once drug resistance 
develops in GNB, there are few options available for treatment. 
K. pneumoniae are encapsulated gram-negative rods commonly found in the environment 
such as soil and water and more importantly, in patients, staff and on surfaces in medical settings. 
As a common nosocomial pathogen, K. pneumoniae are frequently implicated in urinary tract and 
respiratory tract infections [7]. The organism has several virulence factors that make it difficult to 
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treat and destroy. One of the most studied is the capsule; Klebsiella form polysaccharide capsules 
that prevent phagocytosis, which make them harder to destroy in the hospital environment [7, 8]. 
In addition, the outer membrane of the bacteria secretes endotoxins called lipopolysaccharide that 
assist in evading phagocytosis. Other resistance mechanisms include pili that help adhere the 
bacteria to surfaces and the use of siderophores that transport iron to the bacteria for increased 
bacterial growth and dissemination [9]. β-lactam antibiotics such as penicillins, cephalosporins 
and carbapenems are typically the first line of treatment for K. pneumoniae and other gram-
negative bacteria. However, the production of extended-spectrum β-lactamases (ESBLs) and K. 
pneumoniae carbapenemase (KPC) by K. pneumoniae have made the bacteria resistant to most 
available drugs [10]. 
Infections caused by Pseudomonas aeruginosa have been frequently found in patients 
suffering from chronic diseases, particularly in the respiratory tract such as chronic obstructive 
pulmonary disease (COPD) and cystic fibrosis (CF) [11]. P. aeruginosa causes ventilator-
associated pneumonia (VAP), a major source of morbidity and mortality in hospitalized patients, 
particularly those in ICUs [12]. With the widespread use of antibiotics, selective pressure has led 
to an increase in ESBL- and carbapenemase-producing P. aeruginosa [13]. Few antibiotic therapy 
options remain effective and clinicians have returned to the use of colistin, a potentially toxic 
antibiotic, to treat patients with multi-drug resistant (MDR) and extensively drug-resistant (XDR) 
pseudomonal infections [14]. 
Acinetobacter baumannii are gram-negative coccobacilli that have been commonly 
isolated in hospitals in the last two decades. Like other hospital-acquired infections, A. baumannii 
can be transmitted through hand contact or medical devices and equipment.  Similar to other 
bacteria, A. baumannii are able to form biofilms on a variety of surfaces and environments but can 
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also survive in dry environments [15, 16]. It can also spread through airborne droplets making it 
very difficult to control [17]. 
 
1.2 Drug resistance in GNB 
 
Gram-negative bacteria are intrinsically resistant to some antibiotics and may develop 
resistance to others. For example, most GNB, particularly P. aeruginosa, are intrinsically resistant 
to many classes of antibiotics because of the low permeability of the outer membrane and selective 
intake due to porins and efflux pumps [18]. Another method in which GNB acquire drug resistance 
is through the exchange of resistance genes. Genes that encode resistance factors are frequently 
found on plasmids, small strands of self-replicating DNA within the cytoplasm of the bacteria. 
Through horizontal gene transfer, resistance genes are spread among bacterial cells. For example, 
genes that produce ESBLs, resulted from the increased prevalence of plasmid-encoded β-
lactamases among GNB and the subsequent use of other β-lactam antibiotics such as quinolones 
and third generation cephalosporins [19].  
GNB also use biofilms, aggregate cell colonies that adhere tightly to surfaces, to harbor 
resistance genes [20, 21]. Biofilms are groups of tightly connected cells in which horizontal gene 
transfer can occur quickly and unhindered. Biofilms prevent the entry of antibiotics through their 
thick cover and produce toxins that reduce the hosts immune system response [22]. These bacterial 
biofilms are able to grow on inanimate surfaces such as ventilators, catheters, implants, and other 
medical devices, making drug resistant cells more pervasive in hospital environments. 
Another method by which GNB evade antibiotics is through persister cells. Persister 
bacterial cells are non-dividing cells that are able to evade the immune system response and 
antimicrobials because of their slow metabolic processes [22]. These cells usually retain the same 
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resistance pattern as the original population. Bacteria considered as high-persistence (hip) mutants 
have specific hip genes that cause the formation of persisters in a bacterial population [23]. Hip 
mutants, usually a tiny proportion of the bacterial population, remain in the host when other 
bacteria are killed by antibiotics. They then reactivate to become regular growing cells and can 
cause re-infection in the host. When bacteria have both resistance genes and hip genes, they can 
recolonize the host with drug-resistant organisms or continue to reside on surfaces. 
Starting from the late 1980s and early 1990s, GNB, particularly Klebsiella spp., with 
acquired resistance to a range of cephalosporins through the production of ESBLs, spread 
throughout US hospitals [18, 24, 25]. Carbapenems used to treat ESBL- producing GNB were also 
rendered ineffective through the emergence of bacteria producing carbapenemases [25]. Bacteria 
with MDR and XDR have also emerged in recent times. From 1993 to 2004, the prevalence of 
MDR K. pneumoniae, P. aeruginosa, and A. baumannii in ICUs in US hospitals increased from 
5.1% to 13.3%, 1.7% to 9.3%, and 6.7% to 29.9%, respectively [19]. Recently, the National 
Healthcare Safety Network released a report stating that in 2014, 17.8% of all Enterobacteriaceae 
infections in the US were of the EBSL phenotype and 3.6% were carbapenem-resistant [26]. 
Furthermore, by 2014, 12.6% and 32.7% of all P. aeruginosa infections in short-term acute care 
hospitals and long-term acute care hospitals,2 respectively, were MDR [26]. That same year, 
almost 45% and 80% of all A. baumannii infections in short-term acute hospitals and long-term 
acute hospitals in the United States, respectively, were found to be MDR [26]. Due to the fast 
development of resistance in GNB, it is urgent to slow the spread of drug resistance, particularly 
in health care settings where outbreaks can have tragic outcomes. 
  




1.3.1 Hospital transmission of GNB infections 
 
Patients who have a higher risk of HAIs need to be identified and protected early in their 
hospitalizations. Methods of preventing HAIs such as infection control precautions including hand 
hygiene and contact isolation, health care worker education, active screening, and antimicrobial 
stewardship are well known [25, 27, 28]. These methods target the portal of exit and entry, mode 
of transmission, and the reservoir based on the chain of transmission [29]. Identification of 
characteristics of susceptible hosts is also important in order to better allocate resources to patients 
at higher risk of HAIs. 
The causative agents highlighted in this dissertation will be K. pneumoniae, P. aeruginosa, 
and A. baumannii for reasons previously mentioned. As an example, the chain of transmission for 
a catheter-associated urinary tract infection (CAUTI) with K. pneumoniae is depicted in Figure 1. 
The reservoirs for K. pneumoniae in hospital settings include surfaces of medical equipment, hands 
of hospital staff, and the gastrointestinal tract of patients and hospital staff [7]. Through inadequate 
hygiene and sanitary practices of hospital staff or the patient’s own peri-urethral area, K. 
pneumoniae can attach to the urinary catheter and be transmitted to the patient. The GNB then 
enters the patient’s urinary tract by travelling up the catheter-urethral surface. Colonization and/or 
infection by K. pneumoniae occurs if the host immune response cannot destroy the bacteria. K. 
pneumoniae will form capsules around itself, release enzymes that break down host cells, and 
create biofilms that are harder to remove by antimicrobials. Susceptible hosts such as patients with 
impaired immune function may be at higher risk for CAUTIs and characterizing these susceptible 
patients can help provide one more opportunity to prevent infections through focused use of 










1.3.2 Risk factors for GNB HAIs 
 
Many studies have examined risk factors for acquiring GNB and MDR GNB infections in 
hospital settings [20-22, 31-33]. General risk factors for HAIs include use of invasive devices, 
surgery, immunosuppressive agents, previous antibiotic use, older age, length of hospital stay, and 
chronic diseases such as diabetes and cancer [34]. Risk factors for drug resistant GNB are similar: 
previous antibiotic use, residence in long-term acute care facilities, stay in an intensive care unit, 
use of indwelling medical devices, poor functional status, older age, and organ or stem cell 
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transplants [25]. Prior hospitalization is also a significant risk factor for GNB and drug resistant 
GNB HAIs [35-37]. The higher risk of infection due to prior hospitalization may be related to the 
increased contact with healthcare workers and equipment. Patients who are hospitalized multiple 
times may have an even greater risk of HAIs with repeated exposure to hospital settings and may 
have different additional risk factors for GNB infections. 
 
1.3.3 Patients with multiple hospitalizations 
 
Multiple hospital admissions pose a considerable burden on healthcare costs and patient 
morbidity and mortality. In the United States, 12-19% of all discharged patients are re-hospitalized 
for all causes within 30 days of discharge [38-40]. Despite an overall decline in readmissions in 
the last decade, hospitalization and readmission rates for patients with multiple chronic conditions 
have increased [41]. Chronically ill patients such as those with multiple chronic diseases are also 
at high risk of developing HAIs and may fall into a recurring hospitalization cycle since HAIs are 
known to increase risk of subsequent hospitalizations [42, 43]. Healthcare costs for chronically ill 
patients account for over half of the total healthcare expenditures in the US [44]. Thus, it is of 
particular importance to study the risk factors that influence risk of HAIs in this special population 
who have multiple hospitalizations. Prediction models have been created to identify these patients 
at high risk of infection and mortality due to HAIs based on known risk factors and comorbidities 
[45-47]. However, these models do not take into account the longitudinal and changing trajectory 
of adult patients who are repeatedly hospitalized. This dissertation will assess risk factors for GNB 






1.3.4 Repeat HAIs 
 
Repeat HAIs likely result from a combination of general host risk factors such as 
compromised immune function and/or extremes of age, inappropriate or prolonged antibiotic 
therapy and/or failed treatment [20, 48, 49]. However, repeat infections may also be the result of 
organism persistence factors such as biofilms and persister cells [23, 50, 51]. Patients may carry 
persister cells that become activated when exposed to the pressure of hospital environments, 
leading to re-colonization and relapse of the original infection. When exposed to the hospital 
environment multiple times, it is possible that these persistence factors put patients at greater risk 
of acquiring a drug-resistant infection. Previous research on recurrent HAIs have been focused on 
Clostridium difficile, gram-positive bacteria found naturally in the human gut and spread through 
fecal-oral transmission [52]. This research has shown that about half of recurrent C. difficile cases 
are due to reinfection of the original or a new strain and the other half may be through reactivation 
of persistent cells within the host [52, 53]. Both K. pneumoniae and P. aeruginosa are naturally 
part of the human microbiome and may result in the same distribution of reinfections and relapses. 
In contrast, A. baumannii is naturally found in the soil and water surfaces and rarely on human 
skin and may not cause repeat infections through the same mechanisms as K. pneumoniae and P. 
aeruginosa [54]. 
Extensive antibiotic exposure in hospitals could select for drug resistant infections in future 
hospitalizations. While summaries of antimicrobial susceptibility patterns prevalent in a hospital 
are often used to guide empirical antibiotic therapy, these reports are based on aggregate counts 
and may not provide relevant data for an individual patient [55]. Using infection history from prior 
hospitalizations may help to minimize antimicrobial resistant GNB HAIs. One of the goals of this 
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dissertation will be to assess if a larger number of repeat HAIs is associated with an increased 
prevalence of resistant infections within individual patients. 
The specific aims of this dissertation are:  
1) Examine clinical and patient risk factors associated with acquiring at least one gram-negative 
hospital acquired infection in adult patients with multiple hospitalizations.  
2) Systematically review the literature assessing the association between repeat gram-negative 
bacterial infections and changes in antibiotic susceptibility patterns. 
3) Assess the association between repeat gram-negative infections and risk of drug-resistant gram-
negative infection among patients with multiple hospital admissions. 
The conceptual framework of the project is shown in   
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Figure 2. Individuals may enter the hospital system due to a variety of different factors 
including age, chronic diseases, injury, etc. The patients then may develop risk factors for GNBs 
within the hospital such as use of invasive medical devices, antibiotic use, staying in an ICU and 
surgeries. When these patients experience a second or multiple hospitalizations, their prior 
hospitalizations in addition to risk factors from their prior hospitalizations and current 
hospitalization become risk factors for GNB HAIs. Aim 1 will investigate which of these factors 
across hospitalizations increase the risk of GNB HAIs. Once a GNB HAI has occurred, patients 
are at risk of developing repeat infections. When patients are re-hospitalized after acquiring a HAI 
in previous hospitalizations, they may be at greater risk of drug-resistant GNB HAIs. Aims 2 and 
3 will evaluate if there is an association between repeat GNB HAIs and risk of a subsequent drug-




Figure 2: Theoretical framework describing hypothesized risk factors for GNB and 






The overall goal of this dissertation is to identify risk factors for GNB and drug resistant 
GNB infections among patients with multiple hospital admissions. Patients who have multiple 
admissions may be at an increased risk of HAIs due to frequent exposure to the hospital 
environment as well as potential chronic conditions that bring them back to the hospital. However, 
there are few studies that examine the risk of HAIs among patients with multiple hospitalizations. 
Chapter 2 of this dissertation summarizes a retrospective cohort study in which I examined risk 
factors associated with acquiring at least one GNB HAI in adult patients with multiple 
hospitalizations using a longitudinal approach by incorporating prior medical history. 
Chapter 0 summarizes a systematic review of the literature that evaluated the association 
between repeat GNB infections and changes in antibiotic susceptibility patterns. It informs the 
hypothesis that repeat GNB HAIs in patients with multiple hospitalizations result in greater risk  
of a subsequent drug resistance HAI. The review specifically examined studies in which change 
in antibiotic susceptibility in HAIs was evaluated at the individual patient level.  
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I then investigated the relationship between repeat GNB HAIs and antibiotic susceptibility 
patterns. Chapter 4 presents the study conducted to assess the association between repeat GNB 
HAIs and risk of drug resistance among patients with multiple hospital admissions. Finally, 
Chapter 5 summarizes the findings and discusses the public health implications of this research.  
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2. Risk factors for gram-negative hospital-acquired infections 




Risk factors for acquiring Klebsiella pneumoniae, Pseudomonas aeruginosa, and 
Acinetobacter baumannii infections have been widely examined but few studies have incorporated 
multiple hospitalizations into risk models. This study aimed to longitudinally evaluate risk factors 
for hospital-acquired infections (HAI) caused by the three pathogens over multiple 
hospitalizations. Identifying these risk factors will assist in focusing infection control resources on 
the highest risk patients and in decreasing the alarming growth of drug resistance in these three 
pathogens. 
Electronic medical records of adult patients hospitalized ≥2 times in three New York City 
hospitals between 2006-2014 were used to assess the impact of potential risk factors on the time 
to the first GNB HAI. A time-dependent Cox model was developed for each organism. Risk factors 
examined included demographic and clinical factors such as age, sex, insurance, admission source, 
Charlson Comorbidity Index (CCI), chronic diseases, major surgeries, invasive medical device 
use, and antibiotic use.  
Of the 129,372 unique patients, 1,672 (1.3%) acquired K. pneumoniae, 1,127 (0.9%) 
acquired P. aeruginosa, and 262 (0.2%) acquired A. baumannii infections. Older age, mechanical 
ventilation, and increasing days of use of antibiotics decreased the time to infection for all 3 
pathogens. In the K. pneumoniae model, a history of cancer, congestive heart failure, and higher 
CCI also decreased time to infection. In addition, P. aeruginosa infections were associated with 
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admission from a non- healthcare facility and A. baumannii infections with a cancer diagnosis and 
dementia. This study identifies several longitudinal risk factors that can be used to guide infection 
control resources for patients with multiple hospitalizations. Incorporating clinical risk factors that 
change across patients’ medical histories into risk models can enhance targeted infection control 




Hospital-acquired infections (HAIs) are often preventable and yet continue to account for 
a significant number of complications in hospitalized patients. In 2014, a landmark study reported 
that 1 in every 25 patients hospitalized in the United States acquired a HAI [1]. HAIs are associated 
with substantial complications and deaths, particularly among those in intensive care units (ICUs) 
[2, 3]. In older adults, such infections are associated with a two-fold increase in 90-day mortality 
rate and an average of 10 additional days in the hospital [4]. Gram-negative bacteria (GNB) are 
implicated in 20% of HAIs in all hospital settings and 60% of HAIs in ICUs [1, 5].   In hospital 
settings, three of the primary GNB of interest are Klebsiella pneumoniae, Pseudomonas 
aeruginosa, and Acinetobacter baumannii, all of which cause opportunistic infections and are 
named by the World Health Organization as critical pathogens for which new antibiotics are 
urgently needed [6, 27]. 
Patients with multiple hospitalizations, the so-called ’high-cost high-risk’ patients, pose a 
great burden on the hospital system in terms of the associated care and costs [56]. These patients 
tend to be older, sicker and more likely to get HAIs [57-59]. While risk factors for HAIs due to K. 
pneumoniae, P. aeruginosa, or A. baumannii have been widely studied, these factors have been 
identified mostly through cross-sectional studies, which disregard the frequent healthcare 
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exposure, the dynamic health status, and antibiotic use of these high-risk patients [35, 60, 61]. 
General risk factors for GNB HAIs include use of invasive devices, surgery, use of 
immunosuppressive agents, antibiotic use, older age, longer hospital stays, and chronic diseases 
such as diabetes and cancer [1, 62-64]. Many of these factors can change across hospitalizations, 
making cross-sectional risk models problematic for patients with multiple hospitalizations. 
Furthermore, patients with multiple hospitalizations may have different risk profiles than the 
general hospitalized population because of the greater exposure to the hospital environment and 
greater opportunity for infection transmission [65, 66]. By incorporating longitudinal methods in 
infection risk assessment, the complex medical histories of patients can be utilized to accurately 
assess risk over the long-term.  
With availability of electronic medical records, more data are available for longitudinal 
infection risk assessment in hospitals. This study aims to evaluate risk factors for the first infection 
caused by K. pneumoniae, P. aeruginosa, and A. baumannii in patients with multiple 





2.3.1 Study population 
 
The population consisted of adult patients aged 18 years or older hospitalized for any cause 
two or more times between 2006 and 2014 at three New York City (NYC) hospitals that are part 
of a large academic healthcare system, including a 221-bed community hospital and two tertiary 
care hospitals with 657 and 914 beds. These hospitals had over 713,700 discharges of adult patients 
within the 9-year period during which 3.6% of all discharges acquired a HAI. Electronic medical 
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records for these patients were collected from a large clinical research database that included all 
adult patients (≥18 years) discharged between January 1, 2006 and December 31, 2014. The 
database, the development of which has been described in Apte, et. al. [67], included information 
from patient administrative records, clinical and medication records, lab- oratory and antibiotic 
susceptibility reports from blood, urine, respiratory, and wound cultures, and International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis and 
procedure codes from admission and discharge. The database was developed as part of a federally 
funded project, “Health Information Technology to Reduce Healthcare-Associated Infections” 
(National Institute of Nursing Research, R01NR010822). The study was approved by the study 
sites institutional review boards. 
  
2.3.2 Data measures 
 
HAIs were defined as infections that were culture positive three or more calendar days after 
hospital admission and not known to be incubating at the time of hospital admission [68]. The 
outcome was defined as the first HAI caused by K. pneumoniae, P. aeruginosa, or A. baumannii 
which first occurred in the second or subsequent hospitalizations. Patients who had a HAI with 
any of the three GNB in their first hospitalization were excluded from the analysis pertaining to 
the specific GNB. 
Potential risk factors/predictors assessed included age, sex, year of first admission, any stay 
in the ICU, days spent in ICU during each hospitalization, Charlson Comorbidity Index (CCI) [69], 
and chronic diseases present on admission to hospital including diabetes, renal failure, 
malignancies, myocardial infarction, congestive heart failure, peripheral vascular disease, 
cerebrovascular diseases, dementia, chronic pulmonary disease, rheumatic disease, peptic ulcer 
disease, paraplegia, liver disease, HIV/AIDS, hypertension, and hypothyroidism. Also included in 
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the dataset were major surgical procedures (operating room procedure, biopsy, dialysis, 
transplant), insurance (Medicare, Medicaid, commercial, other), admission source (clinic referral, 
non-health care facility, other health care facility, unknown), presence of other infections (other 
GNB, other gram positive infection, other infection), use of invasive medical devices (mechanical 
ventilator, feeding tube, cardiac catheter, vascular stent, CV/IV line), and antibiotic use during 
each hospitalization prior to the occurrence of the GNB infection. Admission from a non-
healthcare facility included walk-ins and patients coming from home. 
  Antibiotics were grouped into the following classes: penicillins, cephalosporins, 
carbapenems, monobactams, polymyxins, anti-MRSA agents (vancomycin, daptomycin, 
ceftaroline, linezolid), aminoglycosides, tetracyclines, macrolides, fluoroquinolones, and other 
(fosfomycin, nitrofurantoin, metronidazole, clindamycin). Penicillins were categorized into four 
groups: natural penicillins, B-lactamase resistant penicillins, aminopenicillins/extended spectrum 
penicillins, and penicillin/inhibitor combinations. Cephalosporins were also categorized by 
generation. Drug resistance was defined by organism as resistant to imipenem and meropenem for 
K. pneumoniae, levofloxacin for P. aeruginosa, and ampicillin/sulbactam for A. baumannii. 
 
2.3.3 Statistical analysis 
 
Separate analyses were conducted for K. pneumoniae, P. aeruginosa, and A. baumannii to  
delineate  the  different  risk  profiles  for  each  GNB  [70].  Bivariate descriptive statistics were 
conducted to assess the association between potential risk factors and specific GNB infection 
through the use of Students t tests, X2 tests, and Fishers exact tests as appropriate. Based on the 
results of these analyses, significant covariates were added in a stepwise fashion in multivariate 
models. The final models for each organism retained covariates significant at the p<0.05, plus age, 
sex, and CCI as a priori covariates. 
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To accommodate the longitudinal nature of multiple hospitalizations and the risk factors 
that vary between each hospitalization, time-varying Cox proportional hazards models were used 
to calculate hazard ratios. Time intervals were set up so that each hospitalization represented one 
interval for each patient. All covariates except sex were allowed to vary over time. The 
proportional hazards assumption was tested and met for each covariate using cox.zph function in 
R [71]. Patients were followed until the hospital day during the second or subsequent 
hospitalization in which the first GNB HAI occurred. Patients who died in the hospital were 
censored to the day of death. Crude and adjusted hazards ratios were calculated for each of the 
potential risk factors. Robust sandwich estimators for the standard errors were used to account for 
any model fitting errors and correlations between the variance due to repeated measures from the 
same patient. Statistical analyses were performed using SAS, version 9.4 (SAS Institute, Cary, 
NC) and R software, version 3.3.2. 
2.4 Results 
 
2.4.1 Incidence of infection 
 
Between 2006-2014, 129,372 patients were hospitalized two or more times (Figure 3). 
After excluding patients who acquired the primary GNB in their first hospitalization, the final 
study sample included 128,746 patients (n=1672 with infection) with 100,285,918 patient-days for 
the K. pneumoniae analysis, 128,936 patients (n=1127 with infection) with 100,576,147 patient-
days for the P. aeruginosa analysis, and 129,281 patients (n=262 with infection) with 101,047,094 
patient-days for the A. baumannii analysis.  The incidence rate of K. pneumoniae infections over 





aeruginosa and A. baumannii, the incidence rates were 1.12 and 0.26 infections per 100,000 
patient-days, respectively.  




Patients had on average 4.6 hospitalizations before acquiring one of the three GNB (Table 
1). The majority of K. pneumoniae and P. aeruginosa infections were urinary tract infections (UTI) 
while A. baumannii infections were primarily pneumonia (PNU) (40%) and UTIs (35%). 









Number of patients 1672 1127 262 
Number of hospital days 118367 79975 23806 
Mean number of hospitalizations to 
infection (range) 
4.6 (2-44) 4.4 (2-49) 4.6 (2-41) 
Site of infection, n (%)       
BSI 296 (18%) 95 (8%) 58 (22%) 
UTI 1056 (63%) 593 (53%) 92 (35%) 
PNU 284 (17%) 373 (33%) 104 (40%) 
SSI 36 (2%) 66 (6%) 8 (3%) 
Number of drug resistant infections 
(%) 




Of the K. pneumoniae infections, 613 (37%) were resistant to imipenem and meropenem. 
Twenty-nine percent (n=330) of P. aeruginosa infections were resistant to levofloxacin and almost 
half of A. baumannii infections (n=116, 44%) were resistant to ampicillin/sulbactam. 
 
2.4.2 Antibiotic use 
 
Table 2 shows antibiotic use among the full study population. Among the antibiotics given 
to the study population, anti-MRSA agents were most frequently given, followed by first 
generation cephalosporins, macrolides, other antibiotics, and third generation cephalosporins. First 
generation cephalosporins were given to the most number of patients, followed by anti-MRSA 
agents, other antibiotics, third generation cephalosporins, and macrolides. Polymyxins and 
carbapenems, typically used to drug-resistant GNB pathogens, were given for the longest average 
duration within hospitalizations. 














Number of days 




Natural penicillins 360 (0.2) 248 (0.3) 5.1 (5.4) 
B-lactamase resistant penicillins 2705 (1.5) 2053 (2.5) 8.4 (8.8) 
Amino/extended spectrum 
penicillins 21377 (11.5) 17292 (21.3) 3.7 (4.7) 
Penicillin/inhibitor combo 1311 (0.7) 1248 (1.5) 1.6 (3.2) 
1st gen Cephalosporins 49746 (26.8) 36088 (44.5) 2.8 (3.6) 
2nd gen Cephalosporins 3119 (1.7) 2874 (3.5) 2.8 (2.7) 
3rd gen Cephalosporins 29049 (15.7) 20711 (25.5) 3.8 (5.0) 
4th gen Cephalosporins 9194 (5.0) 6657 (8.2) 8.2 (12.5) 
Carbapenems 9004 (4.9) 6121 (7.5) 11.2 (16.4) 
Monobactams 5420 (2.9) 4015 (4.9) 6.8 (14.9) 
Polymyxins 1478 (0.8) 1059 (1.3) 14.4 (22.9) 
Anti-MRSA agents 59728 (32.2) 35147 (43.3) 7.4 (13.3) 
Aminoglycosides 19756 (10.7) 14608 (18.0) 5.2 (11.0) 
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Tetracyclines 4378 (2.4) 3377 (4.2) 7.2 (12.3) 
Macrolides 32670 (17.6) 20431 (25.2) 4.2 (5.6) 
Fluoroquinolones 25778 (13.9) 18060 (22.2) 4.9 (8.5) 
Other* 31566 (17.0) 21873 (26.9) 6.6 (11.4) 
*Other category contained antimicrobials used to treat fungal infections and topical drugs. 




Table 3 shows the distribution of clinical characteristics of patients at their first hospitalization, 
grouped by GNB and whether the patient developed an infection. Patients who had a HAI with 
any of the three GNB by the end of the study period were generally older, had higher CCIs, were 
more likely to have diabetes, renal failure, malignancies, congestive heart failure, peripheral 
vascular disease, cerebrovascular disease, chronic pulmonary disease, rheumatic disease, 
hemiplegia/paraplegia, liver disease, HIV/AIDS, and hypertension. For all three pathogens, 
patients were more likely to have stayed in an ICU, taken antibiotics, used mechanical ventilation, 
a feeding tube or a CV line, had a major procedure, have Medicare insurance, and be admitted 




Table 3: Characteristics of patients at their first hospitalization and associations with GNB 
infection, by organism. 
 
 K. pneumoniae P. aeruginosa A. baumannii 
 










71152 (56.0) 0.03 552 (49.0) 71618 (56.0) <0.0001 109 (41.6) 72247 (56.0) <0.0001 
CCI, mean 
(range) 
2.6 (0-13) 1.6 (18.0) <0.0001 2.3 (0-14) 1.6 (0-18) 0.54 2.7 (0-11) 1.6 (0-18) 0.003 














17531 (13.8) <0.0001 243 (21.6) 17764 (13.9) <0.0001 60 (22.9) 18037 (14.0) <0.0001 
Myocardial 
infarction 













125 (7.5) 7230 (5.7) 0.002 104 (9.3) 7278 (5.8) <0.0001 25 (9.5) 7396 (5.8) 0.009 
Dementia 






19210 (15.3) <0.0001 274 (24.4) 19267 (15.2) <0.0001 64 (24.2) 19573 (15.3) <0.0001 
Any liver 
disease 
146 (8.8) 5543 (4.4) <0.0001 58 (5.2) 5664 (4.5) 0.26 15 (5.7) 5718 (4.5) 0.33 
AIDS/HIV 





58050 (46.1) <0.0001 622 (55.4) 58439 (46.2) <0.0001 131 (50.0) 59078 (46.2) 0.22 
Hypothyroi
dism 






0.60 (0-443) <0.0001 3.45 (0-443) 0.61 (0-391) <0.0001 4.87 (0-192) 0.64 (0-443) <0.0001 
Antibiotic 
use, n (%) 
718 
(42.9) 
44009 (34.6) <0.0001 548 (48.6) 44281 (34.7) <0.0001 118 (45.0) 44996 (34.9) 0.0006 
Medical device use, n (%) 
Mechanical 
vent 
107 (6.4) 2870 (2.3) <0.0001 101 (9.0) 2896 (2.3) <0.0001 38 (14.5) 3056 (2.8) <0.0001 
Feeding 
Tube 
49 (2.9) 1135 (0.9) <0.0001 38 (3.4) 1152 (0.9) <0.0001 15 (5.7) 1219 (0.9) <0.0001 
Card 
Catheter 
165 (9.9) 12874 (10.1) 0.72 117 (10.4) 12974 (10.2) 0.8 20 (7.6) 13110 (10.2) 0.18 
Vascular 
stent 




12171 (9.6) <0.0001 210 (18.6) 12347 (9.7) <0.0001 62 (23.7) 12696 (9.8) <0.0001 





31481 (22.8) <0.0001 309 (27.4) 31656 (24.8) <0.0001 71 (27.1) 32095 (24.9) 0.01 
Biopsy 
87 (5.2) 2970 (2.3) <0.0001 45 (4.0) 3029 (2.4) 0.0004 13 (5.0) 3079 (2.4) 0.006 
Dialysis 
84 (5.0) 2628 (2.1) <0.0001 32 (2.8) 2698 (2.1) 0.09 14 (5.3) 2746 (2.1) 0.0003 
Transplant 

















39008 (30.7)  210 (18.6) 39250 (30.7)  57 (21.8) 39483 (30.6)  
Other 




























2.4.4 Time-varying Cox models for first GNB infection 
 
The multivariate cox models developed for the first HAI due to K. pneumoniae, P. 
aeruginosa, or A. baumannii and statistically significant risk factors are summarized in Table 4: 
Time-varying Cox models for acquiring a GNB HAI across multiple hospitalizations, by infecting 
organism. 
 
 K. pneumoniae P. aeruginosa A. baumannii 
 HR 95% CI HR 95% CI HR 95% CI 
Age 1.009 1.006 - 1.012 1.024 1.020 - 1.028 1.008 1.000 - 1.016 
Female 1.315 1.191 - 1.451 1.035 0.919 - 1.166 0.783 0.605 - 1.012 
Charlson Comorbidity 
Index 1.051 1.030 - 1.073 1.007 0.984 - 1.031 1.021 0.966 - 1.080 
Malignancies 1.368 1.198 - 1.561 --    1.596 1.163 - 2.189 
Congestive heart 
failure 1.161 1.034 - 1.303 --    --    
Dementia --    --    2.495 1.557 - 3.999 
Stay in an ICU 2.019 1.797 - 2.270 1.949 1.673 - 2.270 --    
Mechanical ventilation 1.495 1.298 - 1.720 2.404 2.039 - 2.833 1.019 1.003 - 1.035 
Admission from non-
healthcare facility --    0.821 0.722 - 0.934 --    
B-lactamase resistant 
penicillins 1.035 1.017 - 1.054 --    --    
Amino/extended 
spectrum penicillins 1.016 1.006 - 1.026 0.986 0.973 - 0.998 1.019 1.003 - 1.035 
Penicillin/inhibitor 
combo 1.046 1.015 - 1.079 --    1.055 1.022 - 1.089 
1st gen 
Cephalosporins --    1.022 1.007 - 1.038 --    
2nd gen 
Cephalosporins --    --    --    
3rd gen 
Cephalosporins --    1.012 1.005 - 1.020 1.016 1.006 - 1.027 
4th gen 
Cephalosporins --    --    0.982 0.968 - 0.996 
Anti-MRSA agents --    1.006 1.004 - 1.009 1.009 1.004 - 1.013 
Aminoglycosides --    1.007 1.005 - 1.009 1.015 1.007 - 1.022 
Carbapenems 1.011 1.006 - 1.016 0.988 0.983 - 0.994 --    
Fluoroquinolones     1.010 1.005 - 1.015 --    
Monobactams 0.995 0.991 - 0.999 --    --    
Tetracyclines 1.019 1.011 - 1.027 1.009 1.001 - 1.016 --    
Macrolides 1.015 1.009 - 1.022 --    0.977 0.960 - 0.994 




In the K. pneumoniae model, stay in an ICU (Hazard Ratio: 2.019, 95%CI: 1.797-2.27), 
mechanical ventilation (HR: 1.495, 95%CI: 1.298-1.72), malignancies (HR: 1.368, 95%CI: 1.198-
1.561), and female sex (HR: 1.315, 95%CI: 1.191-1.451) were strongly associated with incident 
infection after adjustment of all other significant factors. Older age was also a predictor for K. 
pneumoniae infection. For every one day increase in the use of penicillin/inhibitor combination 
drugs, there was an associated 4.6% increase (95%CI: 1.5-7.9%) in risk of incident  
K. pneumoniae infection, in addition to a 3.5% increase (95%CI: 1.7-5.4%) with β-lactamase 
resistant penicillins, 1.19% increase (95%CI: 1.1-2.7%) with tetracyclines and 1.6% increase 
(95%CI: 0.6-2.6%) with aminopenicillins/extended spectrum penicillins.  There was a slight 
protective effect associated with monobactam use (HR: 0.995, 95%CI: 0.991- 0.999). 
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Table 4: Time-varying Cox models for acquiring a GNB HAI across multiple 
hospitalizations, by infecting organism. 
 
 K. pneumoniae P. aeruginosa A. baumannii 
 HR 95% CI HR 95% CI HR 95% CI 
Age 1.009 1.006 - 1.012 1.024 1.020 - 1.028 1.008 1.000 - 1.016 
Female 1.315 1.191 - 1.451 1.035 0.919 - 1.166 0.783 0.605 - 1.012 
Charlson Comorbidity 
Index 1.051 1.030 - 1.073 1.007 0.984 - 1.031 1.021 0.966 - 1.080 
Malignancies 1.368 1.198 - 1.561 --    1.596 1.163 - 2.189 
Congestive heart failure 1.161 1.034 - 1.303 --    --    
Dementia --    --    2.495 1.557 - 3.999 
Stay in an ICU 2.019 1.797 - 2.270 1.949 1.673 - 2.270 --    
Mechanical ventilation 1.495 1.298 - 1.720 2.404 2.039 - 2.833 1.019 1.003 - 1.035 
Admission from non-
healthcare facility --    0.821 0.722 - 0.934 --    
B-lactamase resistant 
penicillins 1.035 1.017 - 1.054 --    --    
Amino/extended spectrum 
penicillins 1.016 1.006 - 1.026 0.986 0.973 - 0.998 1.019 1.003 - 1.035 
Penicillin/inhibitor combo 1.046 1.015 - 1.079 --    1.055 1.022 - 1.089 
1st gen Cephalosporins --    1.022 1.007 - 1.038 --    
2nd gen Cephalosporins --    --    --    
3rd gen Cephalosporins --    1.012 1.005 - 1.020 1.016 1.006 - 1.027 
4th gen Cephalosporins --    --    0.982 0.968 - 0.996 
Anti-MRSA agents --    1.006 1.004 - 1.009 1.009 1.004 - 1.013 
Aminoglycosides --    1.007 1.005 - 1.009 1.015 1.007 - 1.022 
Carbapenems 1.011 1.006 - 1.016 0.988 0.983 - 0.994 --    
Fluoroquinolones     1.010 1.005 - 1.015 --    
Monobactams 0.995 0.991 - 0.999 --    --    
Tetracyclines 1.019 1.011 - 1.027 1.009 1.001 - 1.016 --    
Macrolides 1.015 1.009 - 1.022 --    0.977 0.960 - 0.994 
Other 1.006 1.003 - 1.010 0.997 0.994 - 0.999 --    
 
Patients who were older (HR: 1.024, 95%CI: 1.02-1.028), experienced an ICU stay (HR: 
1.949, 95%CI: 1.673-2.27), or received mechanical ventilation (HR: 2.404, 95% CI: 2.039-2.833) 
had increased risk of P. aeruginosa infection. Admission from any location other than a healthcare 
facility (e.g., home) and use of aminopenicillins/extended spectrum penicillins, carbapenems, and 
other antibiotics were associated with a decreased risk of P. aeruginosa infection. Patients who 
were given first generation cephalosporins had a 2.2% increased risk for incident infection with 
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each day of use, higher than all other antibiotics. Female sex, the CCI, and other comorbidities 
were not associated with P. aeruginosa infection after controlling for other significant factors. 
Age, sex, and the CCI were not significantly associated with acquiring an A. baumannii 
infection.   Instead, patients who had malignancies (HR:  1.596, 95%CI: 1.163-2.189), dementia 
(HR: 2.495, 95%CI: 1.557-3.999), and mechanical ventilation (HR: 1.019,95%CI: 1.003-1.035) 
were significantly associated with A. baumannii infection. Prior to infection, use of  
aminopenicillins/extended spectrum penicillins, penicillin/inhibitor combinations, third 
generation cephalosporins, anti-MRSA agents, and aminoglycosides increased the hazard of A. 
baumannii infection.  Use of fourth generation cephalosporins and macrolides was associated with 
a decreased risk of infection. 
2.5 Discussion 
 
Patients with multiple hospitalizations represent a unique high-risk group for their frequent 
exposure to a high transmission environment and antibiotic pressure. This study leveraged 
longitudinal electronic medical data to describe a population of patients who experienced multiple 
hospitalizations across a nine-year period and evaluated possible time-varying risk factors for 
acquiring a K. pneumoniae, P. aeruginosa, or A. baumannii infection in the hospital. To our 
knowledge, this study is the first to examine variable risk factors for GNB HAIs across multiple 
years and hospitalizations in these high-risk patients. 
As with prior studies, we found that older age, having an ICU stay, mechanical ventilation, 
and antibiotic use prior to infection were associated with incident GNB HAI after adjusting for 
other variables [61, 72-76]. Increased transmission of GNB infections in the ICU and through the 
use of medical devices such as mechanical ventilators is well-documented [62, 77]. Most recent 
literature examines prior antibiotic use only in determining risk of drug resistance and mortality 
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among hospitalized patients. Among studies that have investigated antibiotic use as a risk factor 
for any GNB HAI, very few have incorporated the duration of treatment into statistical models 
[61, 75]. This study provides evidence that even a single day of a particular antibiotic in the 
hospital can result in an increased risk of a HAI.  
Although there was only a small increased risk of infection with every day of antibiotic 
use, this risk compounds when patients are repeatedly exposed to empirical therapy or treatment 
for other infections. These results may apply to patients with little or no hospitalization history due 
to the widespread outpatient use of antibiotics [78]. Patients who have had extensive exposure to 
antibiotics prior to entering the hospital system may have high risk of developing a drug-resistant 
GNB HAI. Antibiotic stewardship is crucial in both hospital and outpatient settings to reduce 
patients’ risk of GNB HAIs.   
There was no consistent pattern of association between any one antibiotic group and any 
of the three pathogens. For example, in contrast to previous studies, this study found no association 
between the use of cephalosporins with incident K. pneumoniae infection although there was 
increased risk of P. aeruginosa and A. baumannii infections [64, 79, 80]. This may reflect the 
reduction of cephalosporin use due to increased drug resistance in HAIs as well as the prescribing 
patterns for empirical therapy at these particular hospitals [79]. 
Overall, the incidence of K. pneumoniae, P. aeruginosa, or A. baumannii was  
relatively low in our population as compared to other studies [76, 81, 82]. However, among 
patients with multiple hospitalizations, the proportion of drug resistant infections was higher than 
the national average [83]. Not surprisingly, greater use of antibiotics, particularly cephalosporins 
and fluoroquinolones, and long durations of carbapenem and polymyxin use prior to the incident 
infection were associated with increased drug resistance within this population. 
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This study was limited by the use of available electronic medical records from a single 
urban three-hospital system and the fact that data on patients’ medical history outside of these 
hospitals or beyond 2006-2014 were unavailable. We did conduct post- hoc analyses comparing 
patients who had their first hospitalization between 2006-2009 and those between 2010-2014 and 
found little or no difference in the Cox models, indicating that our results may be robust to recent 
time periods (data not shown). In addition, there were slight variations in GNB infection rates by 
year but did not make a statistically significant change in our results.  
Another limitation was that only HAIs detected during hospitalization were included; data 
on HAIs that may have been diagnosed after discharge were not identified unless patients were re-
hospitalized within 30 days. In this study, it was not possible to identify the indications for the 
prior use of antibiotics which may help explain the extended use of carbapenems and polymyxins 
in the sample. 
Despite these limitations, the types of data collected electronically in this study are similar 
to those collected by hospital infection prevention and control systems; therefore, the use of these 
data will help assess the extent to which routinely-collected and electronically-available clinical 
and administrative data can be used for infection risk assessment. Long term electronic medical 
records are being used within automated systems for antibiotic stewardship [84, 85].  However, 
there seems to be a gap in the literature in using long-term patient data for identification of 
infection risk. Future studies to investigate how electronic medical records can be used with 
automated prediction models to improve infection control are indicated. This study provides the 
first step in doing so by demonstrating how infection risk can be predicted in patients with multiple 
hospitalizations. Using such data, it is possible to account for patient changes over time and utilize 
their full hospitalization history to identify high-risk patients. 
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In conclusion, this study quantifies the risk associated with daily use of antibiotics on GNB 
HAI amongst a vulnerable population of hospitalized patients. There is a strong case for improving 




3. Repeat gram-negative hospital-acquired infections and 




Repeat hospital-acquired infections (HAIs) among frequently hospitalized patients 
contribute to the high rates of antibiotic resistance among gram-negative bacteria (GNB) in 
hospital settings. This systematic review examines the state of the literature assessing the 
association between repeat GNB HAIs and changes in antibiotic susceptibility patterns. A 
systematic search of English language published literature was conducted to identify studies in 
peer-reviewed journals from 2000-2015. Studies must have assessed drug resistance in repeat GNB 
infections longitudinally at the patient level. Two researchers independently reviewed search 
results for papers meeting inclusion criteria and extracted data. Risk of bias was assessed using a 
modified quality assessment tool based on the Checklist for Measuring Study Quality and the 
Quality Assessment Checklist for Cases Series.  
From 3,385 articles identified in the search, seven met inclusion criteria. Five reported 
lower antibiotic susceptibility in repeat infections, one found a change but did not specify in which 
direction, and one reported no change. All studies were of low to average quality. Despite the 
dearth of studies, evidence suggests that repeat infections are associated with lower antibiotic 







Over 648,000 patients in US hospitals develop hospital-acquired infections (HAIs), with 
approximately 75,000 of those patients dying due to related complications each year [1]. Almost 
one-third of all HAIs and 60% of HAIs in intensive care units are caused by gram-negative bacteria 
(GNB) [1, 5, 19, 86]. GNB are becoming increasingly resistant to available antibiotics as 
widespread antibiotic use has surged globally [87, 88]. Patients who are repeatedly hospitalized 
are at greater risk for GNB infections and may contract multiple infections throughout their 
hospitalization history [35, 89, 90]. Repeat HAIs among frequently hospitalized patients may be 
contributing to the high rates of antibiotic resistance seen in GNB in hospital settings. Multiple 
infections likely result from a combination of general host risk factors, invasive therapeutic 
interventions, inappropriate or prolonged antibiotic treatment, and organism persistence factors 
such as biofilms and persister cells [20, 23, 48-51]. When exposed to the hospital environment 
multiple times, it is possible that these factors put patients at greater risk of acquiring or developing 
a drug-resistant infection.  
The current literature has extensively described the effect of prior antibiotic use on 
antibiotic resistance and the use of antibiotic stewardship in reducing resistance [91, 92]. However, 
less is known about the role of previous GNB HAIs on antibiotic susceptibility in subsequent HAIs 
with the same organism. This systematic review examines the state of the literature assessing the 
association between repeat GNB HAIs and changes in antibiotic susceptibility patterns. 
3.3 Methods 
 
To be included in the systematic review, articles must have met the following criteria: 1) 
published in a peer-reviewed journal between January 1, 2000 and December 31, 2015, 2) primary 
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research written in English, 3) have an abstract and full text available, 4) assess drug resistance in 
repeat GNB infections longitudinally as a primary or secondary outcome. The search start date of 
January 2000 was chosen to account for the increasing incidence of drug resistant GNB infections 
beginning in the early 2000s in the United States [18, 87]. Articles assessing the effect of treatment 
on an infection were excluded as well as studies that were done solely in CF or COPD patients, 
who have increased risk of recurrent colonization and infection. Other exclusions included single 
patient case studies, articles only studying community-acquired infections, articles focused on 
salmonella and other food-borne diseases, and articles without data at the individual patient level. 
Conference presentations and dissertations were also excluded. 
The search was conducted using the PubMed and Embase databases with a combination of 
Medical Subject Headings (MeSH) and keywords. The search terms are shown in Table 5. A 
professional medical librarian was consulted to review and refine search terms and strategy.  
Table 5: Literature search terms. 
 
Database Date of 
search 
Search terms Number of 
results 
Pubmed 08/05/2016 ((("Gram-Negative Bacteria"[MeSH] and "Drug 
Resistance"[MeSH] AND "Bacterial Infections"[MeSH] 
AND ("Recurrence"[MeSH] or repeat or previous or 
chronic or persistent or persistence or longitudinal))) AND 
( "2000/01/01"[PDat] : "2015/12/31"[PDat] ) AND 
Humans[MeSH] AND English[lang]) 
1367 
Embase 08/05/2016 'drug resistance'/exp OR 'drug resistance' AND ('gram 
negative bacteria'/exp OR 'gram negative bacteria') AND 
('recurrence'/exp OR 'recurrence' OR 'repeat' OR 
'persistent' OR 'longitudinal' OR 'chronic') AND 
[humans]/lim AND [english]/lim AND [2000-2015]/py 
2316 
 
Relevant articles were extracted and stored using reference management software 
(EndNote X7, Thomas Reuters) and duplicates were deleted. Two reviewers, both doctoral 
candidates in epidemiology, independently screened titles and abstracts of articles to determine 
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whether the inclusion criteria were met. Full-text articles were then reviewed by the same two 
reviewers and reference lists of those articles were searched for potentially relevant publications. 
Inconsistencies regarding eligibility assessments between the two reviewers were discussed and 
resolved by consensus. 
The following data were extracted from the final articles: publication journal, publication 
year, country in which the study was conducted, research questions, study time frame, sample, 
study design, analytic approach, organism, determination and definition of repeat infection, and 
findings related to antibiotic susceptibility changes. The quality of the selected studies was 
assessed by both reviewers using a modified quality assessment tool based on the Checklist for 
Measuring Study Quality and the Quality Assessment Checklist for Case Series [93, 94] which 
were developed for observational case series and case-control study designs, respectively. 
Questions relating to study randomization, blinding and interventional aspects were removed as 
they did not apply to the studies in this review. Items were scored as Yes (Y), No (N), Partial (P), 
Unclear/unable to determine (U) and Not applicable (NA) and weighted equally. The overall 
quality of the studies was based on the following scores: Good (G): at least 80% of criteria met; 




The search yielded 3,385 potential articles (Figure 4). After applying the inclusion and 
exclusion criteria, 29 articles were selected for full text review. Seven final articles were identified 
after exclusion for the following reasons: 1) no assessment of antibiotic susceptibility changes over 
time (n=12), 2) only conducted among patients with CF or COPD who have differential and higher 
risk of recurrent infection (n=1) 3) conference abstracts (n=6), 4) no comparison of antibiotic 
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susceptibility changes within the same individual (n=1), and 5) primarily focused on community-
acquired infections (n=2). 




3.4.1 Characteristics of included studies 
 
The included studies were conducted in Australia, Canada, Israel, South Korea, 
Switzerland, Taiwan, and the United States (Table 6) [95-101].  
 
Articles identified through 
Pubmed  
(n = 1367) 
Additional articles 
identified through 
reference lists (n=1) 
Articles after duplicates removed  
(n = 3385) 
Articles excluded for not 
meeting inclusion/exclusion 




(n = 29) 
Full-text articles excluded, 
with reasons (n = 22) 
- 12 deleted because no 
assessment of changes in 
drug resistance over time  
- 1 deleted because no 
comparison between 
isolates of same patient 
- 6 deleted because 
conference abstract 
- 1 deleted because study 
population only CF/COPD 
patients  




Articles included in 
systematic review  
(n = 7) 
Articles identified 
through Embase  
(n = 2316) 
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Table 6: Summary of key characteristics of publications included in the systematic review. 
 






















Patients 18 years of 
age or younger who 
were hospitalized 
from January 1, 











more than 1 
GNB collected 
over more than 
1 date 
39 /147 patients had 
additive DR, including 
10/39 with additive DR 
from cultures across 2 
or more admissions, and 
6/39 patients who 
developed later 
infection/colonization 



















isolations of A. 
baumannii 
separated by at 
least 30 days 
Patients with initial 
carbapenem-resistant 
isolates had more 
closely related isolates 
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*Abbreviations: KLA: Klebsiella-infected liver abscesses; MDR: multi-drug resistant organisms. 
All of them were cohort studies, three prospective and four retrospective. The inclusion 
and exclusion criteria varied across studies; all but one study included only patients with confirmed 
recurrent infection or colonization [96-101]. The Patel et al. study included only patients 18 years 
while the Ram et al., St. Denis et al., Yang et al., and Yum et al. studies included only adults ≥18 
years [95, 96, 98, 100, 101]. The Qi et al. and Reinhardt et al. studies did not provide details on 
the study patients’ age [97, 99]. Two studies recruited patients from multiple hospitals [95, 100]. 
Six of the seven studies included ≤41 patients with recurrent infections; Ram et al. included data 
from 271 patients [95-101] and Patel et al. included 39 patients with drug-resistant isolates 
collected on different dates [95]. One study included only two patients [99].  Organisms examined 
included exclusively Burkholderia cepacia complex (n=1), exclusively Pseudomonas aeruginosa 
(n=2), exclusively Acinetobacter baumannii (n=1), exclusively Klebsiella pneumoniae (n=1), all 
GNB (n=1), and all bacteria (n=1). 
The definition of the timing of repeat infections differed among the studies. One study 
defined recurrent infection as positive cultures at least 30 days apart, another defined recurrence 
as occurring at least one year apart, and another as at least two months after the completion of 
antibiotic therapy [96, 97, 101]. The St. Denis et al. required two or more positive cultures within 
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12 months [100]. Three studies did not describe a specific time difference between positive isolates 
[95, 98, 99].  
 One study did not report any type of statistical analyses [101]. Of the other six studies, one 
used correlations and three used bivariate analyses including χ2 tests, Fisher Exact tests and 
Student’s t-tests [95, 96, 99, 100]. Two studies used logistic regression to calculate odds ratios [97, 
98].  
3.4.2 Antibiotic susceptibility changes in recurrent infections 
 
 Six of the seven studies found that the GNB causing recurrent infections had reduced 
antibiotic susceptibility patterns as compared to initial or early infections [95, 97-100]. The Yang 
et al. study found no change in susceptibility for K. pneumoniae liver abscesses and the Yum et al. 
study did not specify the direction of antibiotic susceptibility changes among the 30% of recurrent 
cases that had a change [96].  
 
3.4.3 Quality assessment 
 
Based on the quality assessment tool, five studies were of average quality and two were 
poor quality (Table 7). None of the studies had adequate power to detect statistically significant 
differences, reported loss-to-follow up rates, or adjusted for different follow up times in their 
analyses or discussions. Only one publication examined potential confounders [98].  
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Table 7: Risk of bias assessment for included studies. 
 
First Author Patel Qi Ram Reinhardt St. Denis Yang Yum 
Study question        
1. 
Is the hypothesis/aim/objective of the study stated in the 
abstract, introduction, or methods section? 
Y Y Y Y Y P Y 
Study population        
2. 
Are the characteristics of the patients included in the 
study clearly described? (number, gender, age, etiology). 
Y Y Y Y Y Y Y 
3. 
Was the case series collected in more than one center? (If 
the study is multicenter, the question should be answered 
'yes'.) 
Y N N N Y N N 
Comparability of subjects/samples        
4. 
Are the eligibility criteria explicit and appropriate? 
(Inclusion and exclusion criteria should be stated.) 
Y P Y Y Y Y N 
5. Were data collected prospectively? N N Y Y Y N N 
6. Were patients recruited consecutively? Y U Y U U U U 
7. 
Did patients enter the study at a similar point in the 
disease? 
Y U Y Y N N U 
8. 
Were the subjects recruited during the same period of 
time? 
Y Y Y Y Y Y Y 
9. Was there loss to follow-up reported? N N N NA N N N 
Outcome measurement (change in antibiotic susceptibility)        
10. 
Are outcomes (primary and secondary) clearly defined in 
the introduction or methodology section? 
Y Y Y Y Y N Y 
11. 
Did the authors use accurate (standard, valid, reliable) 
objective methods to measure the outcomes? (Systematic, 
repeatable methods of case finding and appropriate lab 
definitions used?) 
Y Y Y Y Y P Y 
12. 
Was there assessment of outcome before and after the 
study? 
Y Y Y Y Y Y Y 
13. Was the length of follow-up clearly described/reported? Y Y N Y Y P N 
Statistical analysis        
14. 
Were the statistical tests used to assess the primary 
outcomes appropriate? (No if no statistical tests) 
Y Y Y N Y N Y 
15. 
Have actual probability values been reported (e.g. 0.035 
rather than <0.05) for the primary outcome measurements 
except where the probability value is less than 0.001?  
(NA if Q14 is N) 
Y Y Y NA Y NA N 
16. 
Does the study provide estimates of the random 
variability in the data for the primary outcomes? (e.g. 
standard error, standard deviation, confidence intervals) 
Y Y Y NA Y N N 
17. 
Was there a discussion/assessment of possible 
confounders? 
N N Y N N N N 
Results        
18. Are the main findings of the study clearly described? Y Y Y Y Y Y Y 
19. 
Do the analyses adjust for different lengths of follow-up 
of patients? If follow-up is differential between groups, 
was this controlled for in the design or analysis? 
N N N N N N N 
20. 
Do the study's findings respond to research 
objectives/question(s)? 
Y Y Y Y Y Y Y 
21. 
If any of the results of the study were based on “data 
dredging”, was this made clear? 
NA N Y Y Y N N 
Discussion/Conclusion        
22. Are the conclusions supported by results? Y Y Y Y Y Y Y 




Did the study have sufficient power to detect a clinically 
important effect where the probability value for a 
difference being due to chance is less than 5%? (No if no 
mention of power) 
N N N N N N N 
Total        
 Yes 18 14 19 15 17 7 10 
 No 5 7 5 5 5 12 12 
 Partial 0 1 0 0 1 3 0 
 Unclear/unable to determine 0 2 0 2 1 1 2 
 Quality rating* A A A A A P P 
*The studies rated with respect to quality criteria as follows: Good (G): at least 80% of criteria met; average (A): between 50% 




Hospitalized patients who experience repeat HAIs are understudied yet represent an 
increasingly important group in the effort to slow the spread of antibiotic resistance. Repeat 
infections are due either to an infection with a new strain of an organism or from a relapse of the  
prior infection-causing organism. Both may result in patients developing future drug resistant 
infections. Several studies have examined whether repeat infections represent re-infections with a 
different strain or relapse of prior infections [102-104]. Yet surprisingly, only a few studies have 
examined repeat infections of GNB, despite the devastating outcomes associated with these 
organisms in hospital settings [105-107]. One study published in 1999 examined recurrent gram-
negative bacteremia among patients to identify relapsed infections versus reinfections with a 
different strain of the same organism [108]. However, in this study, 60% of the infections were 
community-acquired. There is a need to assess repeat GNB infections within hospital settings since 
there is a greater chance of acquiring a drug-resistant GNB infection in hospitals [109-111]. 
In this review, we found only seven published studies that examined changes in antibiotic 
susceptibility in GNB among patients with repeat infections since 2000. Increased drug resistance 
was generally found in patients with more repeat infections, suggesting that if initial infections 
were contained, subsequent resistant infections could be prevented. Studies focused on 
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Staphylococcus aureus have identified patients with initial antibiotic-susceptible infections who 
are at higher risk of subsequent resistant infections [4, 112]. 
The quality of the literature included in this review limits our ability to determine with 
strong evidence that there is an increase in antibiotic resistance in repeat hospital-acquired GNB 
infections. The studies, which were of average to low quality, did not have adequate sample sizes 
or statistical power to evaluate if there was a change in antibiotic susceptibility in repeat GNB 
infections. They also differed in the definition of a repeat infection, for example whether the later 
infection occurred 30 days or a year after the initial infection. Additionally, all but one of the 
studies provided only descriptions of occurrence of repeat infections as opposed to risk of 
occurrence of repeat infections with and without drug resistance. Hence, the published literature, 
while suggestive, does not strongly substantiate the association between repeat infections and 
antibiotic susceptibility. 
Future research should not only assess whether there is increased drug resistance in repeat 
GNB infection, but also what patient and hospital risk factors are associated with repeat infections 
and drug resistance. Patients who are older and/or have chronic illnesses are likely at 
disproportionately higher risk of repeat HAI. For example, the Patel et al. paper examined risk 
factors for acquiring a multi-drug resistant infection or multiple infections with resistance to 
multiple drugs and found that patients with more admissions, stay in a long-term care facility, 
higher number of days in an intensive care unit, and higher number of days with a catheter had a 
greater risk of having repeat infections with drug resistance [95]. Identifying risk factors that put 
patients at greater risk for a repeat infection as well greater risk of a drug-resistant infection will 
help in focusing infection prevention and care resources. Future studies should identify larger 
samples of hospitalized patients with repeat infections by using electronic medical records or large 
 43 
 
national data sets that would contain long-term infection history in order to ensure sufficient 
statistical power to identify associations. In addition, future research can assess whether an 
association between repeat GNB infections and lower antibiotic susceptibility is due primarily to 
prior antibiotic exposure in order to guide antibiotic stewardship and other infection control 
initiatives. 
This systematic review has limitations. The inclusion criteria for the review were relatively 
narrow; nevertheless, studies that met our inclusion criteria were heterogeneous in patient samples 
and in their definitions of repeat infections so it was not possible to do a meta-analysis. We may 
have missed articles in the literature search due to other variations in terminology. Finally, there 
is the possibility of publication bias, as we did not include conference abstracts, dissertations, other 




Despite the limitations, this review suggests that repeat GNB infections contribute to drug 
resistance in hospitals and highlights the need for further research. Repeat GNB HAIs most likely 
affect patients with multiple hospitalizations or those who have extensively long hospital stays. 
Repeat GNB infections in patients with multiple hospitalizations, particularly older patients, can 
result in increased complications, higher mortality, increased hospital and patient costs, and greater 
risk of future infections [4]. At a time when drug resistance among GNB is increasingly prevalent, 
reducing repeat infections may lead to fewer drug resistant infections in hospitals and improve 







4. Risk of drug resistance in repeat gram-negative infections 




Drug resistance in gram-negative bacterial hospital-acquired infections (GNB HAIs) has 
become ubiquitous in recent years. Patients who experience multiple hospitalizations are at high 
risk of developing repeat GNB HAIs. This study aims to evaluate the relationship between repeat 
HAIs with two GNB, Klebsiella pneumoniae and Pseudomonas aeruginosa, and antibiotic 
susceptibility patterns in this high-risk group. 
Using electronic medical records from 3 NYC hospitals, 4,053 patients were identified with 
at least one HAI caused by K. pneumoniae or P. aeruginosa over multiple hospitalizations in a 9-
year period. Modified Poisson regression was used to evaluate the risk of drug resistance with 
increasing number of prior infections. Drug resistance was defined as resistant to carbapenems for 
K. pneumoniae and resistant to levofloxacin for P. aeruginosa. 
In patients with repeat infections by the same organism, almost 15% of consecutive 
infections changed from susceptible to drug resistant. Patients with K. pneumoniae infections had 
a 1.14 times increased risk of acquiring a drug-resistant HAI (95%CI:1.04-1.24) with each prior 
HAI, after adjusting for potential confounders and antibiotic use prior to infection. Patients with 
P. aeruginosa infections had a 1.23 times increased risk of a future drug-resistant infection 
(95%CI: 1.12-1.36) with each prior P. aeruginosa HAI. Prevention of repeat infections in 






Rising rates of drug resistance in gram-negative bacteria (GNB) have threatened the gains 
made in reducing hospital-acquired infections (HAIs) around the world [113, 114]. Patients who 
develop drug-resistant HAIs are at greater risk for longer hospital stays, complications, and 
mortality [115-117]. Prevention of infections caused by GNB including K. pneumoniae and P. 
aeruginosa, are particularly critical due to the limited treatment options. In early 2017, the World 
Health Organization declared that P. aeruginosa and Enterobacteriaceae, in particular extended-
spectrum β-lactamase (ESBL) producing K. pneumoniae, were priority pathogens that urgently 
required new antibiotic development due to widespread multi-drug resistance [118]. 
Patients with multiple hospital admissions are a vulnerable group with high risk of HAIs 
[119-121]. These patients are exposed repeatedly to the hospital environment, specifically to 
intensive care units (ICUs), where the combination of compromised immune systems, empiric 
antibiotic therapy and medical devices creates the ideal haven for drug-resistant infections. These 
high-risk patients may experience repeat infections by the same organism, potentially resulting in 
an increased likelihood of developing a drug-resistant infection. 
Repeat infections can lead to drug resistance through several mechanisms such as 
inappropriate antibiotic therapy, biofilms, and persister cells [23, 122, 123]. A number of studies 
have focused on repeat infections due to pathogens such as Escherichia coli and Staphylococcus 
aureus [124-126]. The few studies that have examined repeat GNB infections have primarily 
aimed at identifying risk factors for recurrence and less on antibiotic resistance patterns in the 
repeat infections [127-129]; changes in antibiotic susceptibility with repeat GNB HAIs has been 
largely overlooked. We recently reviewed peer-reviewed literature published between 2000 and 
2015 and found only seven studies that examined changes in drug resistance in GNB HAIs [95-
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101]. Although one recently published study described an association between multidrug 
resistance and history of GNB bloodstream infections [130], the primary objective of the study 
was to measure costs associated with multidrug resistance rather than to focus on recurrent 
infections. 
The aim of our study was to evaluate the association between repeat GNB HAIs and 
antibiotic susceptibility patterns in chronically ill patients who have repeated hospitalizations. It is 
hypothesized that as the number of infections by the same organism increases, there is a greater 




4.3.1 Sample and Setting 
 
Electronic medical record (EMR) data were obtained from a data warehouse, the 
development of which has been described in Apte, et. al. [67], which includes information from 
patient administrative records, clinical and medication records, laboratory and antibiotic 
susceptibility reports from blood, urine, respiratory, and wound cultures, and International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis and 
procedure codes from admission and discharge. The data were from a large healthcare system in 
New York City which consisted of a community hospital and two tertiary care hospitals. The three 
hospitals had over 713,700 discharges of adult patients between 2006 and 2014 and 3.6% of patient 
discharges experienced at least one HAI. The database was developed as part of a federally funded 
project, “Health Information Technology to Reduce Healthcare- Associated Infections” 
(R01NR010822), and was approved by the institutional review boards of the study sites.  
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A subset of data containing records of all adult inpatients (≥ 18 years) discharged between 
January 1, 2006 to December 31, 2014 was used for this study. Patients who were hospitalized two 
or more times during the study period and had at least one HAI caused by K. pneumoniae or P. 
aeruginosa were included in our analyses. These two pathogens were chosen due to their 
pervasiveness in hospital settings. Acinetobacter baumannii was also considered but there were 
not enough patients with repeat infections with the pathogen to warrant analysis. 
  
4.3.2 Data Measures 
 
An infection was considered to be a HAI if there was a positive culture with the organism 
on the third or later calendar day following hospital admission, the infection was not known to be 
incubating at the time of admission, and it met the criteria defined by the National Healthcare 
Safety Network of the Centers for Disease Control and Prevention [68]. In this study, repeat HAIs 
were defined as HAIs that occurred at least 30 days after a previous hospital discharge. Exposure 
to repeat infections was defined as the count of HAI with the same causative organism across ≥2 
hospitalizations during the study period. Patients were considered unexposed to repeat infections 
if they had ≥2 hospital visits but only one GNB HAI across all hospitalizations. In the case of 
multiple GNB infections with the same organism within the same hospitalization, only the first 
infection was included in the analyses to limit bias due to an unresolved initial infection. 
The outcome measure was a binary variable denoting any antimicrobial-resistant infection 
versus an antimicrobial-susceptible infection for the last HAI caused by each organism. K. 
pneumoniae was considered to be drug resistant if it was not susceptible to imipenem or 
meropenem. P. aeruginosa was considered to be drug resistant if it was not susceptible to 
levofloxacin. Among exposed patients (those with ≥ 2 GNB HAIs), only the last HAI with the 
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same organism was assessed for drug resistance. For unexposed patients (those with only one GNB 
HAI across all their hospitalizations), the one GNB HAI was assessed for drug resistance. 
Variables assessed for potential confounding included age, sex, cumulative length of 
hospital stay prior to development of the last GNB HAI, number of total hospitalizations prior to 
the outcome infection, any stay in the intensive care unit (ICU), cumulative number of days in the 
ICU prior to the outcome infection, admission source from hospitalization with the outcome 
infection (clinic referral, non- health care point of origin (e.g., home), other health care facility, 
unknown), major procedures (operating room (OR) procedure, biopsy, dialysis, transplants), use 
of invasive medical devices (mechanical ventilator, feeding tube, cardiac catheter, vascular stent, 
CV/IV line), and co-infections (other GNB, other gram positive infection, other infection). Also, 
included in the dataset were change in the Charlson Comorbidity Index (CCI) [131] from first visit 
to the visit with the last infection as a proxy to measure change in health status across 
hospitalizations, comorbidities (chronic obstructive pulmonary disease (COPD), cystic fibrosis 
(CF), diabetes, malignancies, renal failure, and liver disease) at the last infection, insurance 
(Medicare, Medicaid, commercial, other), and antibiotic use across hospitalizations prior to the 
occurrence of the outcome infection.  
Antibiotics were grouped as follows: penicillins, cephalosporins, carbapenems, 
monobactams, polymyxins, anti-MRSA agents (vancomycin, daptomycin, ceftaroline, linezolid), 
aminoglycosides, tetracyclines, macrolides, fluoroquinolones, and other (fosfomycin, 
nitrofurantoin, metronidazole, clindamycin). 
 
4.3.3 Statistical Analyses 
 
Separate analyses were carried out for each organism, K. pneumoniae and P. aeruginosa. 
Bivariate analyses were conducted to identify any differences between exposed and unexposed 
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patients using Student’s t tests, X2 tests, and Fishers exact tests, as appropriate. A modified Poisson 
regression model was used to analyze the relationship between repeat GNB HAIs and drug 
resistance. In our study population, 33.3% of patients with multiple hospitalizations and at least 
one GNB HAI of interest had a drug-resistant infection so the rare disease assumption was not 
valid. The Poisson model, modified through use of a generalized estimating equations (GEE) 
approach, was used to obtain unbiased robust standard errors for the relative risks [132, 133]. 
Confounding was assessed though calculating the effect size of the β coefficient with and 
without inclusion of the potential confounders, those with a p value ≤0.05 in the bivariate analyses. 
Covariates that resulted in a 10% or greater change in the effect estimate were retained in the final 
model in addition to all antibiotic use. Statistical analyses were performed using SAS, version 9.4 




There were 2,416 patients who had at least one K. pneumoniae HAI and 1,637 who had at 
least one P. aeruginosa HAI across multiple hospitalizations between 2006 and 2014. Of the 
patients who acquired K. pneumoniae, 97 (4%) had repeat K. pneumoniae HAIs. Of the patients 
who acquired P. aeruginosa, 79 (4.8%) had repeat infections. 
Table 8 summarizes the patient demographic, clinical, laboratory, and medication data 
based on whether they had repeat infections by the end of the study period. In the K. pneumoniae 
analysis, patients with two or more infections were younger, had more hospitalizations prior to last 
infection, spent a greater number of days in the hospital and in an ICU, more likely diagnosed with 
COPD, and more likely to have had an OR procedure, biopsy, or transplantation as compared to 
patients who only had one HAI caused by K. pneumoniae. Patients with repeat infections were 
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also more likely to have experienced a feeding tube, mechanical ventilation, intubation, urinary 
catheterization and IV line as well as a greater number of days on all types of antibiotics as 
compared to unexposed patients.  
 
Table 8: Descriptive statistics of study sample, by exposure status. 
 
  K. pneumoniae P. aeruginosa 
  One infection 
Repeat 
infections 














Female sex 1283 (55.33) 46 (47.42) 0.125 789 (50.64) 31 (39.24) 0.048 
Prior hospitalizations, mean (SD) 2.78 (3.93) 6.79 (6.81) <.001 2.62 (3.8) 6.73 (5.76) <.001 




Total prior days in ICU, mean (SD) 10.72 (21.63) 28.54 (37.41) <.001 14.23 (28.65) 28.42 (46.24 <.001 
Drug resistance in last infection 822 (35.45) 55 (56.7) <.001 427 (27.41) 46 (58.23) <.001 
Admission source 
      
Clinic 658 (28.37) 24 (24.74) 
0.018 
448 (28.75) 17 (21.52) 
0.03 
Non-healthcare point of origin 773 (33.33) 23 (23.71) 482 (30.94) 29 (36.71) 
Other facility 303 (13.07) 12 (12.37) 232 (14.89) 5 (6.33) 
Other 585 (25.23) 38 (39.18) 396 (25.42) 28 (35.44) 
Insurance 
      
Medicare 1429 (61.62) 62 (63.92) 
0.548 
1040 (66.75) 59 (74.68) 
0.416 
Medicaid 400 (17.25) 20 (20.62) 244 (15.66) 11 (13.92) 
Commercial 459 (19.79) 14 (14.43) 260 (16.69) 9 (11.39) 
Other 31 (1.34) 1 (1.03) 14 (0.9) 0 (0) 
Prior clinical history* 
      
Prior OR procedure 1123 (48.43) 62 (63.92) 0.003 839 (53.85) 52 (65.82) 0.037 
Prior feeding tube 182 (7.85) 14 (14.43) 0.02 172 (11.04) 24 (30.38) <.001 
Prior mechanical ventilation 571 (24.62) 39 (40.21) <.001 505 (32.41) 38 (48.1) 0.004 
Prior biopsy 268 (11.56) 20 (20.62) 0.007 139 (8.92) 13 (16.46) 0.024 
Prior intubation 473 (20.4) 36 (37.11) <.001 410 (26.32) 33 (41.77) 0.003 
Prior cardiac catheter 399 (17.21) 20 (20.62) 0.384 227 (14.57) 15 (18.99) 0.281 
Prior vascular stent 181 (7.81) 8 (8.25) 0.874 92 (5.91) 3 (3.8) 0.621 
Prior transplant 168 (7.24) 17 (17.53) <.001 103 (6.61) 9 (11.39) 0.101 
Prior urinary catheter 1837 (79.22) 90 (92.78) 0.001 1295 (83.12) 73 (92.41) 0.03 
Prior CV or IV line 1220 (52.61) 76 (78.35) <.001 861 (55.26) 69 (87.34) <.001 
Chronic conditions 
      
COPD 950 (40.97) 54 (55.67) 0.004 703 (45.12) 42 (53.16) 0.161 
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Cystic Fibrosis 77 (3.32) 2 (2.06) 0.769 75 (4.81) 11 (13.92) 0.002 
Diabetes 955 (41.18) 46 (47.42) 0.222 582 (37.36) 33 (41.77) 0.429 
Renal disease 971 (41.87) 49 (50.52) 0.091 612 (39.28) 43 (54.43) 0.007 
Any malignancy 830 (35.79) 33 (34.02) 0.721 494 (31.71) 27 (34.18) 0.646 
HIV/AIDS 56 (2.41) 4 (4.12) 0.302 36 (2.31) 3 (3.8) 0.432 
Hypertension 1798 (77.53) 76 (78.35) 0.85 1197 (76.83) 59 (74.68) 0.66 
Hypothyroidism 395 (17.03) 21 (21.65) 0.238 269 (17.27) 16 (20.25) 0.495 
Change in CCI from 1st hospitalization 
to last hospitalization, mean (SD) 
0.71 (2.27) 0.4 (2.23) 0.185 0.58 (2.07) 0.34 (2.12) 0.316 
Prior antibiotic use (days) 
      
Penicillins, mean (SD) 1.94 (7.6) 4.37 (10.35) 0.002 1.89 (8.82) 2.7 (6.47) 0.421 








Monobactams, mean (SD) 1.02 (14.16) 3.87 (23.46) 0.061 1.17 (12.93) 8.85 (38.52) <.001 












Tetracyclines, mean (SD) 1.16 (9.72) 5.16 (12.73) <.001 1.5 (15.55) 7.9 (33.63) 0.001 












Levofloxacin, mean (SD) 2.83 (12.52) 6.35 (14.23) 0.007 3.12 (16.61) 13 (29.51) <.001 




*Prior history refers to any exposure across all hospitalizations in study time frame prior to the last GNB HAI. 
 
 
Patients who had two or more P. aeruginosa infections compared to patients with only one 
infection were younger, had more hospitalizations, spent a greater number of days in the hospital 
and in an ICU, had a prior OR procedure, had a biopsy, underwent transplantation, were exposed 
to invasive medical devices, and had a diagnosis of cystic fibrosis, and renal disease. These patients 
were also more likely to have taken all antibiotics, except penicillins, for a greater number of days 
compared to patients with one P. aeruginosa infection. 
Patients who had one or more K. pneumoniae HAIs had a total of 2,570 infections (Table 
9). The majority of these were bloodstream infections (63%), followed by pneumonia (19%), 
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urinary tract infections (15%), and surgical site infections (2.8%). However, 65% of surgical site 
infections were drug-resistant while only 35% of bloodstream pathogens were drug-resistant. For 
P. aeruginosa, there were a total of 1,757 HAIs amongst all patients who had at least one infection. 
P. aeruginosa infections tended to be bloodstream (50%) or pneumonia (37%). Pneumonia caused 
by P. aeruginosa had the highest proportion of drug resistance (41%) as compared to other types 
of infection. 
Table 9: Number of total infections in study population, by body site. 
 
  K. pneumoniae P. aeruginosa 
  N = 2570 N = 1757 





Urinary tract infection 373 36.73 122 23.77 
Bloodstream infection 1627 34.54 878 23.80 
Pneumonia 496 41.33 644 40.68 
Surgical site infection 74 64.86 113 23.01 
 
 
When changes in antibiotic susceptibility were evaluated (Figure 5), there was minimal 
change in consecutive K. pneumoniae HAIs; 80% (n=82) remained susceptible or resistant from 
the prior infection. In 15% (n=16) of paired K. pneumoniae infections, the organism was resistant 
in the second infection. In consecutive P. aeruginosa infections, a large proportion of infections 
remained resistant (44%) and 16% (n=14) of second infections were drug-resistant. 
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Figure 5: Consecutive infections and antibiotic susceptibility in patients who had 2 or more 






Table 10 and Table 11 summarize the crude and adjusted relative risks for drug- resistant 
infection for K. pneumoniae and P. aeruginosa, respectively. Poisson models with robust standard 
errors showed that a greater number of prior HAIs resulted in a higher likelihood of drug-resistant 
K. pneumoniae infection (Relative Risk: 1.14, 95%CI: 1.04-1.24) and a greater likelihood of a 
drug-resistant P. aeruginosa infection (RR: 1.23, 95%CI: 1.12-1.36) after adjusting for other 
confounders and antibiotic use. Mechanical ventilation (RR: 1.39, 95%CI: 1.24-1.57) and 
admission from another healthcare facility (RR:1.61, 95%CI: 1.02-1.32) were also associated with 
increased risk of K. pneumoniae infection after adjustment. In the P. aeruginosa model, cystic 




Table 10: Crude and adjusted risk ratios of having a drug resistant K. pneumoniae. 
 
  Crude Adjusted* 
  RR 95% CI RR 95% CI 
Number of infections 1.242 1.141 - 1.352 1.136 1.038 - 1.244 
Prior biopsy 1.205 1.042 - 1.394 1.115 0.956 - 1.300 
Prior transplant 1.311 1.112 - 1.546 1.116 0.939 - 1.326 
Prior days in ICU 1.004 1.003 - 1.006 0.998 0.995 - 1.000 
Prior mechanical ventilation 1.463 1.315 - 1.627 1.391 1.237 - 1.565 
Admission source          
Non-healthcare point of origin Ref    Ref     
Clinic 0.743 0.618 - 0.894 0.766 0.660 - 0.890 
Other healthcare facility 1.138 0.963 - 1.344 1.161 1.021 - 1.320 
Other 0.970 0.820 - 1.146 0.981 0.831 - 1.157 
Prior antibiotic use (days)          
Penicillins 1.009 1.006 - 1.013 1.004 1.001 - 1.008 
Cephalosporins 1.006 1.004 - 1.009 1.001 0.998 - 1.004 
Carbapenems 1.006 1.004 - 1.008 1.003 1.000 - 1.005 
Monobactams 1.002 1.001 - 1.003 0.999 0.997 - 1.002 
Polymyxins 1.010 1.007 - 1.013 1.001 0.998 - 1.004 
Anti-MRSA agents 1.003 1.002 - 1.004 0.999 0.997 - 1.001 
Aminoglycosides 1.006 1.004 - 1.008 1.001 0.999 - 1.004 
Tetracyclines 1.008 1.005 - 1.010 1.004 1.002 - 1.006 
Macrolides 1.005 1.003 - 1.007 1.001 0.998 - 1.004 
Fluoroquinolones 1.007 1.004 - 1.009 1.002 0.998 - 1.005 
Other 1.004 1.002 - 1.006 1.004 1.001 - 1.006 




Table 11: Crude and adjusted risk ratios of having a drug resistant P. aeruginosa. 
  Crude Adjusted* 
  RR 95% CI RR 95% CI 
Number of infections 1.395 1.284 - 1.516 1.232 1.121 - 1.355 
Cystic fibrosis 2.471 2.081  2.934 2.272 1.884  2.739 
Prior antibiotic use (days) 
        
Penicillins 1.004 0.997 - 1.010 1.006 0.999 - 1.014 
Cephalosporins 1.002 1.000 - 1.004 0.997 0.995 - 1.000 
Carbapenems 1.0037 1.0016 - 1.0059 1.003 1.000 - 1.006 
Monobactams 1.003 1.000 - 1.006 0.998 0.995 - 1.002 
Polymyxins 1.006 1.004 - 1.008 0.997 0.992 - 1.001 
Anti-MRSA agents 1.002 1.001 - 1.003 1.000 0.998 - 1.001 
Aminoglycosides 1.008 1.006 - 1.010 1.003 1.000 - 1.006 
Tetracyclines 1.002 0.999 - 1.005 0.997 0.992 - 1.002 
Macrolides 1.005 1.003 - 1.007 1.004 1.002 - 1.007 
Fluoroquinolones 1.007 1.005 - 1.009 1.004 1.001 - 1.007 
Other 1.006 1.005 - 1.007 1.004 1.001 - 1.007 
 




In a population of patients with multiple hospitalizations, more repeat GNB HAIs were 
associated with higher risk of drug-resistant infection. To the best of our knowledge, this study is  
the first to describe the association between repeat GNB HAIs and drug resistance, taking into 
account prior antibiotic use. For each prior hospitalization with a K. pneumoniae HAI, there was 
a 14% increased risk of having a drug-resistant K. pneumoniae HAI in a subsequent 
hospitalization. For patients with repeat P. aeruginosa infections, the risk of drug resistance 
increased by 23% with each prior HAI with P. aeruginosa.  
 Repeat GNB HAIs increased risk of drug-resistant infections after adjusting for antibiotic 
use and other risk factors, indicating that there is some other mechanism through which prior 
infections influence the development of drug resistance. Persister cells are likely a cause for this 
phenomenon as they have been shown to be resistant to antibiotics and difficult to detect and 
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eradicate [134]. Most studies examining persistence factors in bacterial infections have been lab-
based studies focused on S. aureus, E. coli and P. aeruginosa [135-137]; however, there are very 
few patient-based studies. This study demonstrates at the patient level that persistence factors may 
play a role in repeat infections and drug resistance in repeat GNB infections. 
In this study, about 15% of consecutive infections changed from antibiotic susceptible to 
resistant and 38% of consecutive K. pneumoniae infections and 44% of consecutive P. aeruginosa 
infections remained drug resistant. Because our definitions of drug resistance were carbapenems 
for K. pneumoniae and fluoroquinolones for P. aeruginosa, typically considered one of the last 
lines of treatment for infections caused by these organisms, prevention of the first drug resistant 
infection is particularly important. This may be achieved through prioritizing prevention of all 
GNB HAIs to reduce patients’ risk of subsequent infection with drug resistance. 
There are several limitations to this study. The use of electronic medical records from a 
single hospital system does not capture patient medical history from other facilities nor provide an 
in-depth background on the patient. Our data covered a relatively small time frame for many 
patients who may have had hospitalizations outside the time period studied. In addition, there was 
no genotyping data available so it was not possible to assess strain relatedness or confirm whether 
a repeat infection was indeed a new infection. However, in this study, we defined a repeat infection 
as a HAI occurring in a hospitalization at least 30 days after a prior hospital discharge, it is unlikely 
that the infection was an unresolved prior infection. Although the number of patients who had 
repeat HAIs with the same GNB was relatively small, power calculations confirmed that there was 




Using patient history over a nine-year period at three New York City hospitals, this study 
demonstrated the high threat of drug-resistant infections in patient with multiple admissions and 
repeat infections. These high-risk patients may serve as a reservoir for drug-resistant infections in 
hospitals; hence, patients with history of GNB HAIs should be prioritized to prevent repeat 










5.1 Summary of findings 
 
Patients with multiple hospitalizations are at considerable risk for poor hospital outcomes, 
particularly hospital-acquired infections (HAIs), given their high volume of days in the hospital 
environment, exposure to broad spectrum antibiotics, and increased exposure to invasive medical 
devices and procedures. With increasing rates of multidrug resistant gram-negative bacteria (GNB) 
in hospitals, patients with multiple hospitalizations are at particular risk for loss of effective 
treatment options. The overarching goal of this dissertation was to evaluate the risk of acquiring 
GNB and drug resistant GNB HAIs amongst this vulnerable population. Few studies to date have 
investigated the risk of GNB infections in hospitalized patients with a history of prior 
hospitalizations.  For three GNBs that are frequently implicated in HAIs– 
K. pneumoniae, P. aeruginosa, and A. baumannii –with 9 years of electronic health records, I used 
a longitudinal approach to test the hypothesis that infections and antibiotic use in prior 
hospitalizations increase the risk of infections and drug resistance in future hospitalizations. 
In Chapter 2 of this dissertation, I presented an investigation of risk factors associated with 
an incident GNB HAI after a prior hospitalization. Findings corroborated other studies in that older 
age, exposure to an intensive care unit (ICU), antibiotic use, and mechanical ventilation are 
significant risk factors for a GNB HAI. More importantly, analyses demonstrated that risk for 
infection increased with each prior day of antibiotic use. Prior use of carbapenems, cephalosporins, 




As summarized in Chapter 3, I conducted a systematic literature review to assess studies 
that attempted to find an association between repeat GNB HAIs and increasing drug resistance. 
Between 2000 and 2015, only seven studies were found to have studied changes in antibiotic 
susceptibility in GNB HAIs at the patient level. Despite the high risk of bias in these studies, the 
majority reported increased drug resistance in subsequent infections, suggesting that repeated 
infections by GNB could result in lower susceptibility to available drugs. 
To further investigate the association between repeat GNB HAIs and decreased antibiotic 
susceptibility, I analyzed clinical records of patients who had multiple hospitalizations and at least 
one GNB HAI. The analysis in Chapter 4 illustrated the strong association between repeat GNB 





As with all observational studies, this dissertation is not without its limitations. The data 
warehouse used in the empirical analyses was developed through the combination of electronic 
medical records, pharmacy records, and laboratory records and spanned nine years across three 
hospitals [67]. The data went through a rigorous cleaning process and has been used by researchers 
to answer critical questions pertaining to HAIs [138-140]. Nevertheless, as the data were not 
collected for research purposes, there may have been missing data and data entry errors. 
The possibility of unmeasured confounding in the analyses is high due to the complex 
relationship between hospital environments, immunocompromised patients, and antibiotic 
pressure. Although many factors associated with acquiring a GNB HAI have been identified in the 
literature, factors such as previous bed occupants with infection, contaminated water, and level of 
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patient care were not included in these current analyses because these data elements were not 
available [141-143]. Lack of genotyping data also prohibited a comprehensive analysis of repeat 
GNB infections in patients. GNB strain relatedness could not be established to assess if repeat 
infections were new infections or relapses of prior infections. 
The data also contained minimal patient demographic information which prevented any in-
depth analysis of socio-economic status and risk of infection. This lack of data may have led to 
unmeasured confounding in the results. However, insurance status was evaluated and was not 
found to be associated with acquiring a GNB HAI or a repeat infection. 
With very few prior studies examining patients with multiple hospitalizations and repeat 
GNB HAIs, it is difficult to evaluate the external validity of our results. However, the risk factors 
found in Chapter 2 are consistent with what other studies have found to be associated with incident 
GNB HAI including specific antibiotic use [61, 64, 72, 73]. Furthermore, based on the results of 
the systematic review and the basic science literature on bacterial persistence, it is likely that there 
is an association between repeat GNB HAIs and increasing drug resistance [96, 99, 144-147].  
 
5.3 Public health relevance 
 
Despite improvements in antibiotic stewardship and standard safety precautions in the last 
decade, drug resistance among GNB in hospitals has been increasing [1, 148]. For patients who 
experience multiple hospitalizations, this presents a potentially serious concern. These patients are 
at high risk for GNB HAIs but have been largely under-studied. This dissertation is one of the first 
and largest studies examining HAIs in patients with multiple hospitalizations. Using a large 
electronic database with a sizable and diverse patient population, results demonstrated that 
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longitudinal analysis of patient risk factors is feasible and can provide a thorough understanding 
of how infections can be prevented. 
It is important to examine risk of GNB HAIs using a longitudinal or life-course perspective 
to 1) identify high risk patients and 2) identify potentially modifiable risk factors to prevent 
incident and repeat GNB infections. As electronic medical records become more widely utilized, 
it will be easier to evaluate patient risk throughout their medical history. Despite governmental 
support including the 2009 Health Information Technology for Economic and Clinical Health 
(HITECH) Act, only about 55% of healthcare providers had implemented fully integrative 
electronic records by 2014 [149]. In addition, although most healthcare facilities now have some 
form of electronic record, the usability and interoperability of these systems remains   suboptimal 
[150]. 
Identification of high-risk patients can help focus infection prevention and control 
resources on these patients [17]. Given that prior antibiotic pressure and persistence factors are 
associated with the development of antibiotic resistance among GNBs, discerning patients’ prior 
medical history would provide guidance for effective care and treatment.  Having complete 
pharmacy records will be important to evaluate patients’ life-time exposure to antibiotics and 
which remain effective. Future studies can evaluate if such data can be used to predict antibiotic 
susceptibility among patients who are given empiric therapy. Patients’ detailed infection and 
antibiotic use history can also help to guide transitional care for patients at the time of hospital 
discharge to prevent reinfection as well as limit infection transmission within the community, 
nursing homes, and other health care facilities [151, 152]. 
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As our population grows and lives longer with chronic disease, multiple hospitalizations 
are becoming the norm. Further research on high risk patients and their risk for drug-resistant GNB 
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